Cite
Sarantis P, Tzanetatou ED, Ioakeimidou E, et al. Cholangiocarcinoma: the role of genetic and epigenetic factors; current and prospective treatment with checkpoint inhibitors and immunotherapy. Am J Transl Res. 2021;13(12):13246-13260
Sarantis, P., Tzanetatou, E. D., Ioakeimidou, E., Vallilas, C., Androutsakos, T., Damaskos, C., Garmpis, N., Garmpi, A., Papavassiliou, A. G., & Karamouzis, M. V. (2021). Cholangiocarcinoma: the role of genetic and epigenetic factors; current and prospective treatment with checkpoint inhibitors and immunotherapy. American journal of translational research, 13(12), 13246-13260.
Sarantis, Panagiotis, et al. "Cholangiocarcinoma: the role of genetic and epigenetic factors; current and prospective treatment with checkpoint inhibitors and immunotherapy." American journal of translational research vol. 13,12 (2021): 13246-13260.
Sarantis P, Tzanetatou ED, Ioakeimidou E, Vallilas C, Androutsakos T, Damaskos C, Garmpis N, Garmpi A, Papavassiliou AG, Karamouzis MV. Cholangiocarcinoma: the role of genetic and epigenetic factors; current and prospective treatment with checkpoint inhibitors and immunotherapy. Am J Transl Res. 2021 Dec 15;13(12):13246-13260. eCollection 2021. PMID: 35035673; PMCID: PMC8748131.
Copy
Download .nbib